Immunome, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immunome, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.06M, a 392.09% increase year-over-year.
- Immunome, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $229.00K, a 7.51% increase year-over-year.
- Immunome, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $411.00K, a 19.25% decline year-over-year.
- Immunome, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $215.00K, a 74.97% decline year-over-year.
- Immunome, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $913.00K, a 54.89% decline from fiscal 2024.
- Immunome, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $2.02M, a 445.55% increase from fiscal 2023.
- Immunome, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $371.00K, a 1059.38% increase from fiscal 2022.
- Immunome, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $32.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.06M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $229.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $913.00K 10-K · filed 2026-03-03 | |
| 2025-09-30 | $411.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $215.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $213.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $2.02M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $509.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $859.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $171.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $371.00K 10-K · filed 2025-03-19 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $32.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | |
| 2022-03-31 | $32.00K 10-Q · filed 2023-05-05 | |
| 2021-09-30 | $47.00K 10-Q · filed 2022-11-14 | $87.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $21.00K 10-Q · filed 2022-08-05 | $44.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-12 | $26.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $20.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $4.00K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-16 | |
| 2019-12-31 | $5.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |